Editorial: AntibodyPlus therapeutics in oncology: innovative mechanisms, therapeutic strategies, and clinical advances

Front Oncol. 2026 Jun 15:16:1896596. doi: 10.3389/fonc.2026.1896596. eCollection 2026.

Authors

Yuanzhi Chen¹, Pengwei Ren², Heyu Chen³, Maozhou He⁴

Affiliations

¹ School of Medicine, Huaqiao University, Xiamen, China.
² Department of Surgery, Yale University School of Medicine, New Haven, CT, United States.
³ AstraZeneca, Gaithersburg, MD, United States.
⁴ School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.

No abstract available

Keywords: AntibodyPlus; antibody engineering; antibody therapy; cancer immunotherapy; tumor microenvironment modulation.

Publication types

Editorial